IRIS Accounts Production v24.2.0.383 11826246 director 1.8.23 31.7.24 31.7.24 false true false false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh118262462023-07-31118262462024-07-31118262462023-08-012024-07-31118262462022-07-31118262462022-08-012023-07-31118262462023-07-3111826246ns15:EnglandWales2023-08-012024-07-3111826246ns14:PoundSterling2023-08-012024-07-3111826246ns10:Director12023-08-012024-07-3111826246ns10:PrivateLimitedCompanyLtd2023-08-012024-07-3111826246ns10:SmallEntities2023-08-012024-07-3111826246ns10:AuditExempt-NoAccountantsReport2023-08-012024-07-3111826246ns10:SmallCompaniesRegimeForDirectorsReport2023-08-012024-07-3111826246ns10:SmallCompaniesRegimeForAccounts2023-08-012024-07-3111826246ns10:FullAccounts2023-08-012024-07-311182624612023-08-012024-07-3111826246ns10:OrdinaryShareClass12023-08-012024-07-3111826246ns10:RegisteredOffice2023-08-012024-07-3111826246ns5:CurrentFinancialInstruments2024-07-3111826246ns5:CurrentFinancialInstruments2023-07-3111826246ns5:ShareCapital2024-07-3111826246ns5:ShareCapital2023-07-3111826246ns5:RetainedEarningsAccumulatedLosses2024-07-3111826246ns5:RetainedEarningsAccumulatedLosses2023-07-3111826246ns5:IntangibleAssetsOtherThanGoodwill2023-08-012024-07-3111826246ns5:PatentsTrademarksLicencesConcessionsSimilar2023-08-012024-07-3111826246ns5:ComputerSoftware2023-08-012024-07-3111826246ns5:PlantMachinery2023-08-012024-07-3111826246ns5:PatentsTrademarksLicencesConcessionsSimilar2023-07-3111826246ns5:ComputerSoftware2023-07-3111826246ns5:PatentsTrademarksLicencesConcessionsSimilar2024-07-3111826246ns5:ComputerSoftware2024-07-3111826246ns5:PatentsTrademarksLicencesConcessionsSimilar2023-07-3111826246ns5:ComputerSoftware2023-07-3111826246ns5:FurnitureFittings2023-07-3111826246ns5:ComputerEquipment2023-07-3111826246ns5:FurnitureFittings2023-08-012024-07-3111826246ns5:ComputerEquipment2023-08-012024-07-3111826246ns5:FurnitureFittings2024-07-3111826246ns5:ComputerEquipment2024-07-3111826246ns5:FurnitureFittings2023-07-3111826246ns5:ComputerEquipment2023-07-3111826246ns5:WithinOneYearns5:CurrentFinancialInstruments2024-07-3111826246ns5:WithinOneYearns5:CurrentFinancialInstruments2023-07-3111826246ns10:OrdinaryShareClass12024-07-31
REGISTERED NUMBER: 11826246 (England and Wales)















PERENNIAL PHARMA LTD

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JULY 2024






PERENNIAL PHARMA LTD (REGISTERED NUMBER: 11826246)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


PERENNIAL PHARMA LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 31 JULY 2024







DIRECTOR: J L Durbidge





REGISTERED OFFICE: 2nd Floor
Titan Court
3 Bishop Square
Hatfield
Hertfordshire
AL10 9NA





REGISTERED NUMBER: 11826246 (England and Wales)





ACCOUNTANTS: Spurling Cannon
King Arthur’s Court
Maidstone Road
Charing
Kent
TN27 0JS

PERENNIAL PHARMA LTD (REGISTERED NUMBER: 11826246)

BALANCE SHEET
31 JULY 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 354,564 292,077
Tangible assets 5 618 1,256
355,182 293,333

CURRENT ASSETS
Stocks 360,824 469,519
Debtors 6 1,761,035 870,409
Cash at bank and in hand 349,740 308,343
2,471,599 1,648,271
CREDITORS
Amounts falling due within one year 7 2,152,602 1,484,774
NET CURRENT ASSETS 318,997 163,497
TOTAL ASSETS LESS CURRENT
LIABILITIES

674,179

456,830

CAPITAL AND RESERVES
Called up share capital 8 100,000 100
Retained earnings 574,179 456,730
SHAREHOLDERS' FUNDS 674,179 456,830

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 July 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 July 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

PERENNIAL PHARMA LTD (REGISTERED NUMBER: 11826246)

BALANCE SHEET - continued
31 JULY 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 9 September 2024 and were signed by:





J L Durbidge - Director


PERENNIAL PHARMA LTD (REGISTERED NUMBER: 11826246)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2024

1. STATUTORY INFORMATION

Perennial Pharma Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of nil years.

Computer software is being amortised evenly over its estimated useful life of nil years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - Straight line over 3 years

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2023 - 2 ) .

PERENNIAL PHARMA LTD (REGISTERED NUMBER: 11826246)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JULY 2024

4. INTANGIBLE FIXED ASSETS
Patents
and Computer
licences software Totals
£    £    £   
COST OR VALUATION
At 1 August 2023 288,400 19,362 307,762
Additions 69,453 - 69,453
Disposals (117,897 ) - (117,897 )
Revaluations 136,000 - 136,000
At 31 July 2024 375,956 19,362 395,318
AMORTISATION
At 1 August 2023 7,940 7,745 15,685
Amortisation for year 35,785 3,872 39,657
Eliminated on disposal (14,588 ) - (14,588 )
At 31 July 2024 29,137 11,617 40,754
NET BOOK VALUE
At 31 July 2024 346,819 7,745 354,564
At 31 July 2023 280,460 11,617 292,077

Cost or valuation at 31 July 2024 is represented by:

Patents
and Computer
licences software Totals
£    £    £   
Valuation in 2023 209,000 - 209,000
Valuation in 2024 166,956 19,362 186,318
375,956 19,362 395,318

5. TANGIBLE FIXED ASSETS
Fixture & Computer
Fittings equipment Totals
£    £    £   
COST
At 1 August 2023
and 31 July 2024 1,318 1,587 2,905
DEPRECIATION
At 1 August 2023 591 1,058 1,649
Charge for year 109 529 638
At 31 July 2024 700 1,587 2,287
NET BOOK VALUE
At 31 July 2024 618 - 618
At 31 July 2023 727 529 1,256

PERENNIAL PHARMA LTD (REGISTERED NUMBER: 11826246)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JULY 2024

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 1,661,135 870,409
Called up share capital not paid 99,900 -
1,761,035 870,409

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts 660,000 660,000
Trade creditors 1,319,051 729,192
Corporation Tax 71,022 43,263
VAT 83,422 41,566
Directors' current accounts 9,595 9,075
Accrued expenses 9,512 1,678
2,152,602 1,484,774

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
100 Ordinary 1 100,000 100